202272-68-2

Basic information

• Product Name: GW2974
• Synonyms: N~4~-(1-Benzyl-1H-indazol-5-yl)-N~6~,N~6~-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine; pyrido[3,4-d]pyrimidine-4,6-diamine, N~6~,N~6~-dimethyl-N~4~-[1-(phenylmethyl)-1H-indazol-5-yl]-
• CAS NO: 202272-68-2
• Molecular Formula: C23H21N7
• Molecular Weight: 395.468
• Mol File: 202272-68-2.mol

Chemical Properties

• Boiling Point: 645.6°C at 760 mmHg
• Flash Point: 344.3°C
• Appearance: yellow/
• Density: 1.3g/cm³
• Vapor Pressure: 1.47E-16mmHg at 25°C
• Refractive Index: 1.71
• Solubility: DMSO: ≥20mg/mL
• CAS DataBase Reference: GW2974(CAS DataBase Reference)
• NIST Chemistry Reference: GW2974(202272-68-2)
• EPA Substance Registry System: GW2974(202272-68-2)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 202272-68-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C23H21N7/c1-29(2)22-11-19-20(13-24-22)25-15-26-23(19)28-18-8-9-21-17(10-18)12-27-30(21)14-16-6-4-3-5-7-16/h3-13,15H,14H2,1-2H3,(H,25,26,28)

Upstream product

• 124-40-3 dimethyl amine 
• 202272-67-1 (1-benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 23856-21-5 1-benzyl-1H-indazol-5-ylamine 
• 23856-20-4 5-nitro-1-(phenylmethyl)-1H-indazole 
• 189680-98-6 6-dimethylamino-3H-pyrido[3,4-d]pyrimidin-4-one 
• 5401-94-5 5-nitroindazole 
• 171178-46-4 5-[N-(tert-butoxycarbonyl)amino]-2-chloropyridine-4-carboxylic acid 
• 171178-45-3 tert-butyl (6-chloropyridin-3-yl)carbamate 
• 58483-95-7 5‐amino‐2‐chloropyridine‐4‐carboxylic acid 
• 171178-48-6 4,6-dichloro-pyrido<3,4-d>pyrimidine 
• 171178-47-5 6-chloro-3H-pyrido[3,4-d]pyrimidin-4-one 
• 100-39-0 benzyl bromide 
• 189680-99-7 4-chloro-6-(N,N-dimethylamino)-pyrido[3,4-d]pyrimidine 

Relevant articles and documents

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Described herein is the design and synthesis of indazolylaminopyridopyrimidines and quinazolines as inhibitors of the class 1 tyrosine kinase receptor family. Data is presented for N4-(1-benzyl-1H-indazol-5-yl)-N6,N6- dime

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S(O)m, wherein m is as defined above, the heterocyclic ring containing a total of 1, 2 or 3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused, with the provisos that the heterocyclic ring does not form part of a purine and that the fused heterocyclic ring does not contain two adjacent O or S(O)matoms. U represents a 5 to 10-membered mono or bicyclic ring system in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S(O)m, wherein m is 0, 1 or 2 and wherein the ring system is substituted by at least one independently selected R6group and is optionally substituted by at least one independently selected R4group, with the proviso that U does not represent phenyl; are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.